Application of oxygen vacancy defects in enhanced anti-cancer nanomedicine

被引:6
|
作者
Gao, Yuan [1 ]
Liu, Shuangqing [1 ]
Liu, Hui [1 ]
Ge, Haiyan [1 ]
Zhang, Meng [1 ]
Zhao, Chunyu [1 ]
Gong, Yufang [1 ]
Zhang, Xinyu [1 ]
Wang, Chao [1 ]
Sun, Xiao [1 ]
Wu, Zhengyan [2 ]
机构
[1] Shandong First Med Univ & Shandong Acad Med Sci, Med Sci & Technol Innovat Ctr, Sch Chem & Pharmaceut Engn, Jinan 250000, Peoples R China
[2] Chinese Acad Sci, Hefei Inst Phys Sci, Key Lab High Magnet Field & Ion Beam Phys Biol, Hefei 230031, Peoples R China
基金
中国国家自然科学基金;
关键词
oxygen vacancy; electron-hole pairs; nanomedicine; catalytic therapy; cancer theranostics; DRUG-DELIVERY; OXIDE NANOPARTICLES; METAL-OXIDES; PHOTOTHERMAL PERFORMANCE; CATALYTIC APPLICATIONS; SYNERGISTIC THERAPY; SPECIES GENERATION; REDUCTION REACTION; ZINC-OXIDE; NM LASER;
D O I
10.1007/s11426-023-1693-8
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Nanomedicine has become an important development direction of modern medicine, and provides a new way for cancer theranostics. To extend the superior physicochemical property of nanomedicine and enhance their role in cancer theranostics, various strategies have been proposed. Among them, the introduction of oxygen vacancies can enhance the separation of electron-hole pairs and improve the nanomaterials' catalytic activity, which is beneficial for cancer diagnosis and treatment. This review briefly summarized the formation mechanism and preparation methods of various oxygen vacancy nanomaterials. Then, the effect and application of various oxygen vacancy nanomaterials, such as iron, manganese, titanium, zinc, bismuth, tungsten, cerium, and molybdenum-based nanomaterials in enhancing cancer theranostics were highlighted. At last, the prospect and challenges of oxygen vacancy nanomaterials were discussed. This review provided an overview of the relevant information on oxygen vacancy in cancer theranostics, and further promoted the development of cancer nanomedicine.
引用
收藏
页码:2492 / 2512
页数:21
相关论文
共 50 条
  • [31] Anti-cancer drugs
    Bergmann-Leitner, ES
    CURRENT PHARMACEUTICAL DESIGN, 2005, 11 (09) : 1077 - 1078
  • [32] ANTI-CANCER ORGANIZATION
    PANTIN, CG
    JOURNAL OF CLINICAL PATHOLOGY, 1971, 24 (05) : 478 - &
  • [33] ANTI-CANCER IMMUNITY
    YAMAMURA, Y
    JOURNAL OF THE JAPANESE SOCIETY OF INTERNAL MEDICINE, 1981, 70 (02): : 33 - 34
  • [34] An anti-cancer Smurf
    Zhao, Keji
    Shi, Yun-Bo
    CELL AND BIOSCIENCE, 2012, 2
  • [35] Anti-cancer drugs
    Bergmann-Leitner, Elke
    CURRENT PHARMACEUTICAL DESIGN, 2008, 14 (11) : 1048 - 1048
  • [36] AN ANTI-CANCER DIET
    GRADY, D
    SIWOLOP, S
    DISCOVER, 1984, 5 (06): : 23 - 26
  • [37] Cytotoxic anti-cancer
    Faure, Sebastien
    ACTUALITES PHARMACEUTIQUES, 2010, 49 (497): : 51 - 54
  • [38] Anti-cancer serum
    不详
    BRITISH MEDICAL JOURNAL, 1935, 1935 : 114 - 115
  • [39] An anti-cancer Smurf
    Keji Zhao
    Yun-Bo Shi
    Cell & Bioscience, 2
  • [40] Anti-Cancer Drugs
    Bergmann-Leitner, Elke
    CURRENT PHARMACEUTICAL DESIGN, 2009, 15 (07) : 730 - 731